{"id":"https://openalex.org/W3083026664","doi":"https://doi.org/10.1158/1078-0432.ccr-20-0645","title":"Phase Ib Study of Ribociclib plus Fulvestrant and Ribociclib plus Fulvestrant plus PI3K Inhibitor (Alpelisib or Buparlisib) for HR+ Advanced Breast Cancer","display_name":"Phase Ib Study of Ribociclib plus Fulvestrant and Ribociclib plus Fulvestrant plus PI3K Inhibitor (Alpelisib or Buparlisib) for HR+ Advanced Breast Cancer","alternate_titles":[],"publication_year":2021,"publication_date":"2021-01-15","ids":{"openalex":"https://openalex.org/W3083026664","doi":"https://doi.org/10.1158/1078-0432.ccr-20-0645","mag":"3083026664","pmid":"https://pubmed.ncbi.nlm.nih.gov/32887722"},"language":"en","primary_location":{"id":"doi:10.1158/1078-0432.ccr-20-0645","doi":"https://doi.org/10.1158/1078-0432.ccr-20-0645","is_oa":false,"landing_page_url":"https://doi.org/10.1158/1078-0432.ccr-20-0645","pdf_url":null,"source":{"id":"https://openalex.org/S183149254","display_name":"Clinical Cancer Research","issn_l":"1078-0432","issn":["1078-0432","1557-3265"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-b","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320273","host_organization_name":"American Association for Cancer Research","host_organization_lineage":["https://openalex.org/P4310320273"],"host_organization_lineage_names":["American Association for Cancer Research"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Clinical Cancer Research","raw_type":"journal-article"},"parent_works":[],"lineage":["https://openalex.org/W3083026664"],"child_works_count":0,"type":"article","is_traditional":true,"indexed_in":["crossref","pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5069056507","display_name":"Sara M. Tolaney","orcid":"https://orcid.org/0000-0002-5940-8671","observed_orcids":["https://orcid.org/0000-0002-5940-8671"]},"institutions":[{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":true,"contributor_roles":[],"raw_author_name":"Sara M. Tolaney","raw_affiliation_strings":["1Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts","institution_ids":["https://openalex.org/I4210117453"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5089465499","display_name":"Young\u2010Hyuck Im","orcid":"https://orcid.org/0000-0001-6459-8118","observed_orcids":["https://orcid.org/0000-0001-6459-8118"]},"institutions":[{"id":"https://openalex.org/I848706","display_name":"Sungkyunkwan University","ror":"https://ror.org/04q78tk20","country_code":"KR","type":"education","lineage":["https://openalex.org/I848706"]}],"countries":["KR"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Young-Hyuck Im","raw_affiliation_strings":["2Department of Medicine, Sungkyunkwan University, Seoul, South Korea"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"2Department of Medicine, Sungkyunkwan University, Seoul, South Korea","institution_ids":["https://openalex.org/I848706"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5053069942","display_name":"Emiliano Calvo","orcid":"https://orcid.org/0000-0003-4921-829X","observed_orcids":["https://orcid.org/0000-0003-4921-829X"]},"institutions":[{"id":"https://openalex.org/I4210137474","display_name":"Hospital Universitario HM Sanchinarro","ror":"https://ror.org/04jep6391","country_code":"ES","type":"healthcare","lineage":["https://openalex.org/I4210122338","https://openalex.org/I4210137474"]}],"countries":["ES"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Emiliano Calvo","raw_affiliation_strings":["3Medical Oncology, START Madrid-CIOCC, Centro Integral Oncol\u00f3gico Clara Campal, Hospital HM Madrid Norte Sanchinarro, Madrid, Spain"],"raw_orcid":"https://orcid.org/0000-0003-4921-829X","affiliations":[{"raw_affiliation_string":"3Medical Oncology, START Madrid-CIOCC, Centro Integral Oncol\u00f3gico Clara Campal, Hospital HM Madrid Norte Sanchinarro, Madrid, Spain","institution_ids":["https://openalex.org/I4210137474"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5009846821","display_name":"Yen\u2010Shen Lu","orcid":"https://orcid.org/0000-0001-7461-1291","observed_orcids":["https://orcid.org/0000-0001-7461-1291"]},"institutions":[{"id":"https://openalex.org/I4210131804","display_name":"National Taiwan University Hospital","ror":"https://ror.org/03nteze27","country_code":"TW","type":"healthcare","lineage":["https://openalex.org/I4210131804"]}],"countries":["TW"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Yen-Shen Lu","raw_affiliation_strings":["4Department of Oncology, National Taiwan University Hospital, Taipei City, Taiwan"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"4Department of Oncology, National Taiwan University Hospital, Taipei City, Taiwan","institution_ids":["https://openalex.org/I4210131804"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5003060935","display_name":"Erika Paige Hamilton","orcid":"https://orcid.org/0000-0002-1911-0336","observed_orcids":["https://orcid.org/0000-0002-1911-0336"]},"institutions":[{"id":"https://openalex.org/I4210135086","display_name":"Tennessee Oncology","ror":"https://ror.org/03754ky26","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210135086"]}],"countries":["US"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Erika Hamilton","raw_affiliation_strings":["5Breast and Gynecologic Cancer Research Program, Sarah Cannon Research Institute/Tennessee Oncology, Nashville, Tennessee"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"5Breast and Gynecologic Cancer Research Program, Sarah Cannon Research Institute/Tennessee Oncology, Nashville, Tennessee","institution_ids":["https://openalex.org/I4210135086"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5046549002","display_name":"Andres Forero","orcid":"https://orcid.org/0000-0002-1360-1695","observed_orcids":["https://orcid.org/0000-0002-1360-1695"]},"institutions":[{"id":"https://openalex.org/I99319750","display_name":"Seagen (United States)","ror":"https://ror.org/01vwesc15","country_code":"US","type":"company","lineage":["https://openalex.org/I99319750"]}],"countries":["US"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Andres Forero-Torres","raw_affiliation_strings":["6Clinical Affairs, Seattle Genetics, Seattle, Washington"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"6Clinical Affairs, Seattle Genetics, Seattle, Washington","institution_ids":["https://openalex.org/I99319750"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5041410352","display_name":"Thomas Bachelot","orcid":"https://orcid.org/0000-0002-0866-9484","observed_orcids":["https://orcid.org/0000-0002-0866-9484"]},"institutions":[{"id":"https://openalex.org/I4210105738","display_name":"Centre L\u00e9on B\u00e9rard","ror":"https://ror.org/01cmnjq37","country_code":"FR","type":"nonprofit","lineage":["https://openalex.org/I4210105738"]}],"countries":["FR"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Thomas Bachelot","raw_affiliation_strings":["7Medical Oncology Department, L\u00e9on-B\u00e9rard Centre, Lyon, France"],"raw_orcid":"https://orcid.org/0000-0002-0866-9484","affiliations":[{"raw_affiliation_string":"7Medical Oncology Department, L\u00e9on-B\u00e9rard Centre, Lyon, France","institution_ids":["https://openalex.org/I4210105738"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5109438941","display_name":"Michela Maur","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210109058","display_name":"Azienda Ospedaliero-Universitaria di Modena","ror":"https://ror.org/01hmmsr16","country_code":"IT","type":"healthcare","lineage":["https://openalex.org/I4210109058"]}],"countries":["IT"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Michela Maur","raw_affiliation_strings":["8Department of Oncology and Hematology, University Hospital of Modena, Modena, Italy"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"8Department of Oncology and Hematology, University Hospital of Modena, Modena, Italy","institution_ids":["https://openalex.org/I4210109058"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5083760620","display_name":"Angelica Fasolo","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210133214","display_name":"IRCCS Ospedale San Raffaele","ror":"https://ror.org/039zxt351","country_code":"IT","type":"healthcare","lineage":["https://openalex.org/I4210133214","https://openalex.org/I4210153126"]}],"countries":["IT"],"is_corresponding":true,"contributor_roles":[],"raw_author_name":"Angelica Fasolo","raw_affiliation_strings":["9Department of Medical Oncology, San Raffaele Hospital \u2013 Scientific Institute, Milan, Italy"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"9Department of Medical Oncology, San Raffaele Hospital \u2013 Scientific Institute, Milan, Italy","institution_ids":["https://openalex.org/I4210133214"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5089355202","display_name":"Ralph Tiedt","orcid":"https://orcid.org/0000-0002-9825-859X","observed_orcids":["https://orcid.org/0000-0002-9825-859X"]},"institutions":[{"id":"https://openalex.org/I1283582996","display_name":"Novartis (Switzerland)","ror":"https://ror.org/02f9zrr09","country_code":"CH","type":"company","lineage":["https://openalex.org/I1283582996"]},{"id":"https://openalex.org/I4400600974","display_name":"Novartis Institutes for BioMedical Research","ror":"https://ror.org/053gv2m95","country_code":"CH","type":"funder","lineage":["https://openalex.org/I1283582996","https://openalex.org/I4400600974"]}],"countries":["CH"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Ralph Tiedt","raw_affiliation_strings":["10Oncology Disease Area, Novartis Pharma AG, Novartis Institutes for BioMedical Research, Basel, Switzerland"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"10Oncology Disease Area, Novartis Pharma AG, Novartis Institutes for BioMedical Research, Basel, Switzerland","institution_ids":["https://openalex.org/I1283582996","https://openalex.org/I4400600974"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5007173790","display_name":"Lisa Nardi","orcid":"https://orcid.org/0000-0002-0990-5901","observed_orcids":["https://orcid.org/0000-0002-0990-5901"]},"institutions":[{"id":"https://openalex.org/I4210117619","display_name":"Novartis (United States)","ror":"https://ror.org/028fhxy95","country_code":"US","type":"company","lineage":["https://openalex.org/I1283582996","https://openalex.org/I4210117619"]}],"countries":["US"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Lisa Nardi","raw_affiliation_strings":["11Translational Clinical Oncology, Novartis, East Hanover, New Jersey"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"11Translational Clinical Oncology, Novartis, East Hanover, New Jersey","institution_ids":["https://openalex.org/I4210117619"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5084841849","display_name":"Uz M. Stammberger","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1283582996","display_name":"Novartis (Switzerland)","ror":"https://ror.org/02f9zrr09","country_code":"CH","type":"company","lineage":["https://openalex.org/I1283582996"]},{"id":"https://openalex.org/I4400600974","display_name":"Novartis Institutes for BioMedical Research","ror":"https://ror.org/053gv2m95","country_code":"CH","type":"funder","lineage":["https://openalex.org/I1283582996","https://openalex.org/I4400600974"]}],"countries":["CH"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Uz Stammberger","raw_affiliation_strings":["12Translational Clinical Oncology, Novartis Pharma AG, Novartis Institutes for BioMedical Research, Basel, Switzerland"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"12Translational Clinical Oncology, Novartis Pharma AG, Novartis Institutes for BioMedical Research, Basel, Switzerland","institution_ids":["https://openalex.org/I1283582996","https://openalex.org/I4400600974"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5102018126","display_name":"Ahmed M. Abdelhady","orcid":"https://orcid.org/0000-0001-9404-5397","observed_orcids":["https://orcid.org/0000-0001-9404-5397"]},"institutions":[{"id":"https://openalex.org/I4210117619","display_name":"Novartis (United States)","ror":"https://ror.org/028fhxy95","country_code":"US","type":"company","lineage":["https://openalex.org/I1283582996","https://openalex.org/I4210117619"]}],"countries":["US"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Ahmed M. Abdelhady","raw_affiliation_strings":["13Clinical Oncology, Novartis, East Hanover, New Jersey"],"raw_orcid":"https://orcid.org/0000-0001-9404-5397","affiliations":[{"raw_affiliation_string":"13Clinical Oncology, Novartis, East Hanover, New Jersey","institution_ids":["https://openalex.org/I4210117619"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5001641186","display_name":"Shiling Ruan","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Shiling Ruan","raw_affiliation_strings":["14Early Clinical Biostatistics, Novartis, East Hanover, New Jersey"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"14Early Clinical Biostatistics, Novartis, East Hanover, New Jersey","institution_ids":[]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5033700679","display_name":"Soo Chin Lee","orcid":"https://orcid.org/0000-0002-5835-6419","observed_orcids":["https://orcid.org/0000-0002-5835-6419"]},"institutions":[{"id":"https://openalex.org/I4210103786","display_name":"National University Cancer Institute, Singapore","ror":"https://ror.org/025yypj46","country_code":"SG","type":"education","lineage":["https://openalex.org/I165932596","https://openalex.org/I4210103786","https://openalex.org/I4210150261"]},{"id":"https://openalex.org/I4210146690","display_name":"National University Hospital","ror":"https://ror.org/04fp9fm22","country_code":"SG","type":"healthcare","lineage":["https://openalex.org/I165932596","https://openalex.org/I4210146690","https://openalex.org/I4210150261"]},{"id":"https://openalex.org/I4210150261","display_name":"National University Health System","ror":"https://ror.org/05tjjsh18","country_code":"SG","type":"education","lineage":["https://openalex.org/I165932596","https://openalex.org/I4210150261"]}],"countries":["SG"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Soo Chin Lee","raw_affiliation_strings":["15Department of Haematology-Oncology, National University Hospital, National University Cancer Institute, National University Health System, Singapore"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"15Department of Haematology-Oncology, National University Hospital, National University Cancer Institute, National University Health System, Singapore","institution_ids":["https://openalex.org/I4210103786","https://openalex.org/I4210146690","https://openalex.org/I4210150261"]}]}],"institutions":[],"countries_distinct_count":8,"institutions_distinct_count":15,"corresponding_author_ids":["https://openalex.org/A5069056507","https://openalex.org/A5083760620"],"corresponding_institution_ids":["https://openalex.org/I4210117453","https://openalex.org/I4210133214"],"apc_list":null,"apc_paid":null,"fwci":2.4504,"has_fulltext":false,"cited_by_count":43,"citation_normalized_percentile":{"value":0.92484633,"is_in_top_1_percent":false,"is_in_top_10_percent":true},"cited_by_percentile_year":{"min":96,"max":99},"biblio":{"volume":"27","issue":"2","first_page":"418","last_page":"428"},"is_retracted":false,"is_pulled":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T12829","display_name":"Advanced Breast Cancer Therapies","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T12829","display_name":"Advanced Breast Cancer Therapies","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10183","display_name":"Breast Cancer Treatment Studies","score":0.0,"subfield":{"id":"https://openalex.org/subfields/1306","display_name":"Cancer Research"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T11914","display_name":"PARP inhibition in cancer therapy","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/ribociclib","display_name":"ribociclib","score":0.9940000176429749},{"id":"https://openalex.org/keywords/fulvestrant","display_name":"fulvestrant","score":0.9990000128746033},{"id":"https://openalex.org/keywords/hr-her2-breast-cancer","display_name":"hormone receptor-positive HER2-negative breast cancer","score":0.8299999833106995},{"id":"https://openalex.org/keywords/advanced-breast-cancer","display_name":"advanced breast cancer","score":0.8820000290870667},{"id":"https://openalex.org/keywords/cdk4-6-inhibitors","display_name":"CDK4/6 inhibitors","score":0.9010000228881836},{"id":"https://openalex.org/keywords/pi3k-inhibitors","display_name":"PI3K inhibitors","score":0.9259999990463257},{"id":"https://openalex.org/keywords/alpelisib","display_name":"alpelisib","score":0.9919999837875366},{"id":"https://openalex.org/keywords/buparlisib","display_name":"buparlisib","score":1.0},{"id":"https://openalex.org/keywords/endocrine-resistance","display_name":"endocrine therapy resistance","score":0.8339999914169312},{"id":"https://openalex.org/keywords/triple-combination-therapy","display_name":"triple combination therapy","score":0.6460000276565552},{"id":"https://openalex.org/keywords/recommended-phase-ii-dose","display_name":"recommended phase 2 dose","score":0.7990000247955322},{"id":"https://openalex.org/keywords/drug-safety-and-tolerability","display_name":"drug safety and tolerability","score":0.8029999732971191},{"id":"https://openalex.org/keywords/drug-drug-interactions","display_name":"drug-drug interactions","score":0.5740000009536743},{"id":"https://openalex.org/keywords/pharmacokinetics","display_name":"pharmacokinetics","score":0.5989999771118164}],"concepts":[{"id":"https://openalex.org/C2780482068","wikidata":"https://www.wikidata.org/wiki/Q5508491","display_name":"Fulvestrant","level":5,"score":0.9540495872497559},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.8218463063240051},{"id":"https://openalex.org/C2778375690","wikidata":"https://www.wikidata.org/wiki/Q7814214","display_name":"Tolerability","level":3,"score":0.6566188931465149},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.5935413837432861},{"id":"https://openalex.org/C197934379","wikidata":"https://www.wikidata.org/wiki/Q2047938","display_name":"Adverse effect","level":2,"score":0.45317843556404114},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.42354580760002136},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.42138999700546265},{"id":"https://openalex.org/C530470458","wikidata":"https://www.wikidata.org/wiki/Q128581","display_name":"Breast cancer","level":3,"score":0.3936786353588104},{"id":"https://openalex.org/C84606932","wikidata":"https://www.wikidata.org/wiki/Q416496","display_name":"Estrogen receptor","level":4,"score":0.08917132019996643}],"mesh":[{"descriptor_ui":"D000077267","descriptor_name":"Fulvestrant","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000631","descriptor_name":"Aminopyridines","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D000971","descriptor_name":"Antineoplastic Combined Chemotherapy Protocols","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D001943","descriptor_name":"Breast Neoplasms","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D001943","descriptor_name":"Breast Neoplasms","qualifier_ui":"Q000235","qualifier_name":"genetics","is_major_topic":true},{"descriptor_ui":"D005260","descriptor_name":"Female","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D009025","descriptor_name":"Morpholines","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D011687","descriptor_name":"Purines","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D011960","descriptor_name":"Receptors, Estrogen","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D013844","descriptor_name":"Thiazoles","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D019869","descriptor_name":"Phosphatidylinositol 3-Kinases","qualifier_ui":null,"qualifier_name":null,"is_major_topic":true},{"descriptor_ui":"D051358","descriptor_name":"Cyclin-Dependent Kinase 4","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false}],"locations_count":3,"locations":[{"id":"doi:10.1158/1078-0432.ccr-20-0645","doi":"https://doi.org/10.1158/1078-0432.ccr-20-0645","is_oa":false,"landing_page_url":"https://doi.org/10.1158/1078-0432.ccr-20-0645","pdf_url":null,"source":{"id":"https://openalex.org/S183149254","display_name":"Clinical Cancer Research","issn_l":"1078-0432","issn":["1078-0432","1557-3265"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-b","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320273","host_organization_name":"American Association for Cancer Research","host_organization_lineage":["https://openalex.org/P4310320273"],"host_organization_lineage_names":["American Association for Cancer Research"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Clinical Cancer Research","raw_type":"journal-article"},{"id":"pmid:32887722","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/32887722","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Clinical cancer research : an official journal of the American Association for Cancer Research","raw_type":"Journal Article"},{"id":"pmh:oai:HAL:hal-04884230v1","doi":null,"is_oa":false,"landing_page_url":"https://hal.science/hal-04884230","pdf_url":null,"source":{"id":"https://openalex.org/S4306402512","display_name":"HAL","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I4405252976","host_organization_name":"Centre pour la Communication Scientifique Directe","host_organization_lineage":["https://openalex.org/I4405252976"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":"Clinical Cancer Research, 2021, 27 (2), pp.418-428. &#x27E8;10.1158/1078-0432.CCR-20-0645&#x27E9;","raw_type":"info:eu-repo/semantics/article"}],"best_oa_location":null,"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being","score":0.9922999739646912}],"study_designs":[{"id":"https://openalex.org/study-designs/clinical-trial","display_name":"Clinical Trial"}],"awards":[],"funders":[{"id":"https://openalex.org/F4320310388","display_name":"Novartis Pharmaceuticals Corporation","ror":"https://ror.org/028fhxy95"}],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":35,"referenced_works":["https://openalex.org/W2014001512","https://openalex.org/W2033672070","https://openalex.org/W2045985885","https://openalex.org/W2137177885","https://openalex.org/W2165404212","https://openalex.org/W2167188058","https://openalex.org/W2290950904","https://openalex.org/W2337490679","https://openalex.org/W2346465624","https://openalex.org/W2396559747","https://openalex.org/W2513801928","https://openalex.org/W2552099557","https://openalex.org/W2558360748","https://openalex.org/W2560635244","https://openalex.org/W2605170315","https://openalex.org/W2614543224","https://openalex.org/W2617437931","https://openalex.org/W2619858681","https://openalex.org/W2775764871","https://openalex.org/W2786945112","https://openalex.org/W2802776309","https://openalex.org/W2804105316","https://openalex.org/W2804378061","https://openalex.org/W2805363969","https://openalex.org/W2805575723","https://openalex.org/W2896846857","https://openalex.org/W2904293303","https://openalex.org/W2925092419","https://openalex.org/W2945564879","https://openalex.org/W2948069739","https://openalex.org/W2976415870","https://openalex.org/W3133509869","https://openalex.org/W4205331907","https://openalex.org/W4239051461","https://openalex.org/W7073554169"],"related_works":["https://openalex.org/W2594791480","https://openalex.org/W2740186708","https://openalex.org/W4200380534","https://openalex.org/W4223442080","https://openalex.org/W7129295489","https://openalex.org/W2467861600","https://openalex.org/W4399150934","https://openalex.org/W3170495568","https://openalex.org/W4416772922","https://openalex.org/W2739622482"],"abstract_inverted_index":{"Purpose:":[0],"Resistance":[1],"to":[2,114,161],"treatment":[3,74,227],"with":[4,9,64,137,183,230,236],"endocrine":[5],"therapy":[6],"in":[7,185,193,196,209,225],"patients":[8,229],"HR+,":[10,65,231],"HER2\u2212":[11,66,232],"advanced":[12],"breast":[13],"cancer":[14],"(ABC)":[15],"is":[16],"common":[17],"and":[18,23,39,43,52,124],"dual":[19],"inhibition":[20],"of":[21,30,41,72,110,175,199,228],"CDK4/6":[22,48],"PI3K":[24],"pathways":[25],"may":[26],"delay":[27],"the":[28,37,47,134,139,155,169,176,197,210,226],"development":[29],"resistance.":[31],"This":[32],"phase":[33,58,106,246],"Ib":[34,59],"trial":[35],"evaluates":[36],"safety":[38,173,224],"tolerability":[40],"triple":[42,135,156,212],"double":[44],"regimens":[45],"containing":[46],"inhibitor":[49],"ribociclib.":[50],"Patients":[51],"Methods:":[53],"In":[54],"this":[55],"open-label,":[56],"multicenter,":[57],"study,":[60],"70":[61],"postmenopausal":[62],"women":[63],"ABC":[67],"were":[68,181],"enrolled":[69],"into":[70],"one":[71],"four":[73],"combinations:":[75],"ribociclib":[76,87,92,98,111,142,177,194],"(once":[77],"daily,":[78],"3":[79],"weeks":[80,119],"on,":[81,120],"1":[82,121],"week":[83,122],"off)":[84,123],"plus":[85,90,93,95,99,101,129,145,149,178,221,240],"fulvestrant;":[86,91,96],"(continuous":[88,127],"dosing)":[89,128],"alpelisib":[94,170,237],"or":[97,238],"buparlisib":[100,146,211,239],"fulvestrant.":[102],"Results:":[103],"The":[104,172,202],"recommended":[105,244],"II":[107,247],"dose":[108],"(RP2D)":[109],"was":[112,141,158,166,189,207],"confirmed":[113],"be":[115],"600":[116],"mg":[117,126,144,148],"(3":[118],"400":[125,143],"fulvestrant":[130,150,179,222,241],"500":[131,151],"mg.":[132,152],"For":[133],"combination":[136,213],"buparlisib,":[138],"RP2D":[140,165],"30":[147],"Enrollment":[153],"for":[154,168,245],"combinations":[157,180,235],"stopped":[159],"due":[160],"unexpected":[162],"toxicity.":[163],"No":[164],"determined":[167],"combination.":[171],"profiles":[174],"consistent":[182],"those":[184],"previous":[186],"studies.":[187],"There":[188],"no":[190],"marked":[191],"difference":[192],"exposure":[195],"presence":[198],"triple-combination":[200],"partners.":[201],"highest":[203],"overall":[204],"response":[205],"rate":[206],"seen":[208],"(25.0%;":[214],"95%":[215],"confidence":[216],"interval,":[217],"9.8\u201346.7).":[218],"Conclusions:":[219],"Ribociclib":[220],"demonstrated":[223],"ABC.":[233],"Triple":[234],"are":[242],"not":[243],"investigation.":[248],"See":[249],"related":[250],"commentary":[251],"by":[252],"Clark":[253],"et":[254],"al.,":[255],"p.":[256],"371":[257]},"cited_by_api_url":"https://api.openalex.org/works?filter=cites:W3083026664","counts_by_year":[{"year":2026,"cited_by_count":6},{"year":2025,"cited_by_count":10},{"year":2024,"cited_by_count":8},{"year":2023,"cited_by_count":10},{"year":2022,"cited_by_count":4},{"year":2021,"cited_by_count":5}],"updated_date":"2026-11-20T13:11:24.684918","created_date":"2020-09-11T00:00:00"}
